Article

Accommodating IOL available in quarter-diopter steps

The FDA has approved the marketing of an accommodating IOL (Crystalens AO, Bausch + Lomb) in quarter-diopter steps in the United States.

Aliso Viejo, CA

-The FDA has approved the marketing of an accommodating IOL (Crystalens AO, Bausch + Lomb) in quarter-diopter steps in the United States.

The company began shipping the lens in the additional diopter steps in mid-May.

The FDA first approved this implant in 2003, and it remains the only FDA-approved accommodating lens. The IOL, now in its fifth generation, also recently received new technology IOL (NTIOL) status from the Centers for Medicare and Medicaid Services.

Quarter-diopter steps are available for two models of the lens (AT50AO, AT52AO), in the ranges of 18 to 22 D. A wider dioptric range should be available by the end of the year, according to the company.

"Quarter-diopter steps for the Crystalens Five-0 and HD have been enthusiastically accepted by surgeons, so we have now added them to the AO model," said Tom Frinzi, vice president of global commercial operations, Bausch + Lomb Surgical. "We still remain the only presbyopic channel lenses available in the United States in quarter-diopter steps and the only presbyopic lens with NTIOL status."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.